Trial Profile
A multiparameter approach to examine the off-target effects of dasatinib in patients with Chronic Myelogenous Leukemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Nov 2017
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Biomarker; Pharmacodynamics
- 24 Nov 2017 New trial record